Trial Profile
A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Elderly Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Aluminium hydroxide (Primary) ; HIL 214 (Primary) ; Monophosphoryl lipid A (Primary)
- Indications Norovirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Takeda
- 17 Jun 2020 Results published in the Vaccine
- 04 Feb 2018 Status changed from active, no longer recruiting to completed.
- 08 Oct 2017 Interim results presented at the IDWeek 2017